Australia markets closed

Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
194.37+13.38 (+7.39%)
At close: 4:00PM EDT
196.00 +1.63 (0.84%)
Pre-market: 05:32AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close180.99
Open180.51
Bid196.00 x 800
Ask0.00 x 800
Day's range179.67 - 195.61
52-week range70.00 - 331.68
Volume4,627,542
Avg. volume3,797,779
Market cap14.402B
Beta (5Y monthly)1.55
PE ratio (TTM)N/A
EPS (TTM)-9.51
Earnings date09 Aug 2021 - 13 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est258.00
  • Why Moderna Just Booked Another $3 Billion in Vaccine Orders and No One Cared
    Motley Fool

    Why Moderna Just Booked Another $3 Billion in Vaccine Orders and No One Cared

    Any way you look at it, Moderna (NASDAQ: MRNA) is on a roll. Here's why Moderna just booked another $3 billion in vaccine orders and no one seemed to care. Moderna announced last week that the U.S. government was buying another 200 million doses of its COVID-19 vaccine.

  • Yahoo Finance Video

    Delta COVID-19 variant likely to become dominant U.S. strain: Doctor

    Dr. Susannah Hills, Pediatric Airway surgeon and assistant professor of ENT at Columbia University Medical Center, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

  • Is Now the Time to Go All-In On Novavax Stock?
    Motley Fool

    Is Now the Time to Go All-In On Novavax Stock?

    On June 14, Novavax (NASDAQ: NVAX) announced that its recombinant nanoparticle coronavirus vaccine, NVX-CoV2373, had demonstrated 93% overall efficacy against coronavirus variants in phase 3 trials -- and that number shot up to 100% for severe or critical COVID-19. The vaccine candidate was also well-tolerated, with serious adverse events spread out equally between placebo and treatment groups. Shares fell about 10% after Novavax published the results.